Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Feb 2019
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms Dapa-HF
- Sponsors AstraZeneca
- 12 Oct 2018 Planned End Date changed from 5 Dec 2019 to 4 Dec 2019.
- 12 Oct 2018 Planned primary completion date changed from 5 Dec 2019 to 4 Dec 2019.
- 27 Aug 2018 Status changed from recruiting to active, no longer recruiting.